Archive | 2017 Rayno Biopharmaceuticals Portfolio

The Rayno Biopharmaceuticals Portfolio up to date picks for 2017 are below.  We have recovered from the bear market for biotechnology stocks since the 2015 “bubble” peak of July 17, 2015. The sector bottomed on November 3, 2016 with IBB at  $246 and is up 19% YTD.

Rayno Life Science Portfolio 2011 H1 Update-Biopharm Big Winners:BIIB, CBST, REGN, SGEN

2011 A Huge Year for Life Science Investing As of mid-year the Rayno Life Science Biopharmaceutical Portfolio was up over 20% beating most  ETF’s and Life Science mutual funds. Our two recommended biotech ETF’s for balancing and overweighting were FBT up 13.3% and IBB up 15.3%. Returns could have been much higher with rebalancing strategies […]

Continue Reading 0

Rayno Biopharma Portfolio: Update 4/11,6/11, and 11/11,21/11

11/18 Added Dendreon (DNDN) at $8.00 level.IBB is preferred biotech ETF. 11/15/11 Comments: Under review: ImmunoGen (IMGN) Dropped FBT an ETF in favor of  IBB or possibly XBI. For bullish equity allocation in Tech and Biotech use QQQ. 6/20/11 NASDAQ (2632) Market stabilizing after 7% correction.QQQ down <1%. IBB up 10% YTD. Mid-cap biopharms are up […]

Continue Reading 0